Printer Friendly

CVRx Receives Innovator of the Year Award; Company Recognized for Developing Implantable Medical Device to Treat High Blood Pressure.

MINNEAPOLIS -- CVRx Inc., a private company that has developed an implantable medical device to treat high blood pressure, announced today that Dr. Robert Kieval, as president and chief executive officer, received a Finance and Commerce Innovator of the Year 2006 award. Dr. Kieval, a company founder, and the CVRx team have developed the Rheos(TM) Baroreflex Hypertension Therapy(TM) System, which is intended for use in patients who cannot control their blood pressure with medications and lifestyle modifications.

"In just a few years, our exceptional team has advanced a promising concept to the point where we are now providing therapy to patients in clinical trials, and we are delighted with the results thus far," said Kieval. "We have demonstrated that Rheos can reduce blood pressure in patients, and we are working closely with the FDA on plans for a pivotal clinical trial of our product. This unique approach to managing high blood pressure has the potential to improve the lives of patients with high blood pressure and prevent more serious disease."

Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications. High blood pressure, or hypertension, affects about 65 million people in the United States. It is a leading cause of stroke, heart attack, heart failure and kidney disease and causes an estimated one in every eight deaths worldwide.

About CVRx: CVRx was founded in 2001. The Rheos System is an implantable device that is designed to reduce blood pressure by using mild electrical signals to influence the body's blood pressure regulation system, known as the baroreflex. This investigational device is currently in clinical trials in Europe and the United States. For more information visit

About Finance & Commerce: Finance and Commerce is the only daily newspaper in the Minneapolis and St. Paul area that is devoted exclusively to business. Each year Finance & Commerce recognizes pioneering companies that have demonstrated an innovative spirit and developed creative products and solutions.

CAUTION: CVRx Rheos System is an investigational device and is limited by Federal (or United States) law to investigational use only.

CVRx, Rheos, Baroreflex Hypertension Therapy are trademarks of CVRx, Inc. (C) CVRx, Inc. 2005
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 23, 2006
Previous Article:Courts Dismiss Securities Class Action Suits against Digimarc Corporation and Executives; Courts Rule Plaintiffs Failed to State a Case against the...
Next Article:Greater Sooner Holdings, Inc. Enhances Fully Permitted Saltwater Disposal Well Capable of Disposing over 1,000,000 Barrels Per Year.

Related Articles
Transplant drug a clue to hypertension?
Drugs slash stroke risk for elderly.
Shocking survival.
Heart pump extends patients' survival.
Medtronic CareLink(R) Network Reaches Significant Patient Milestones; First Internet-Based System to Better Manage Chronic Cardiovascular Disease...
Clinical Trial Findings Show Significant Reduction in Blood Pressure with CVRx(R) Rheos(TM) Baroreflex Hypertension Therapy(TM) System.
Digital Angel Corporation and Verichip Corporation Form Joint Committee to Design and Develop Implantable Glucose-Sensing Microchip.
European and U.S. Clinical Trial Findings Show Significant Reduction in Blood Pressure with CVRx(R) Rheos(TM) Baroreflex Hypertension Therapy(TM)...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters